CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Valeritas, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Valeritas, Inc.
750 US Highway 202 Ste 600
Phone: (908) 927-9920p:908 927-9920 BRIDGEWATER, NJ  08807-2597  United States Fax: (845) 818-3588f:845 818-3588
The Company’s Plan of Liquidation went into effect on 6/30/2020
Valeritas, Inc. filed a Registration Withdrawal Request of its Form S-1 (File No. 333-202057) with the SEC on 3/10/2016. The market conditions have been such that the offering of Registrant’s common stock will not be consummated.
This is a Subsidiary, click here for the Parent Company
Business Summary
Valeritas, Inc. is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company's portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin. Its development portfolio also includes the h-Patch technology, the Mini-Ject pre-filled needle-free delivery system and the Micro-Trans microneedle transdermal delivery patch. Its h-Patch is a controlled delivery technology platform designed to deliver drugs into subcutaneous tissue. The Mini-Ject represents needle-free injection system, combining a range of fully disposable pre-filled options. Micro-Trans microneedle array patch technology enables drug delivery into the dermis without limitations of drug size, structure, charge or the patient's skin characteristics.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201412/31/2014YesYesYes-Yes

Industries
SIC Code Description
3841 Surgical and medical instruments and apparatus
3842 Orthopedic, prosthetic, and surgical appliances and supplies

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Daniel A.Pelak 9/1/2011 9/1/2011
President and Chief Commercial Officer, Interim Chief Executive Officer John E.Timberlake 53 2/25/2016 8/1/2008
Executive Vice President - Manufacturing, Operations and Research & Development GeoffreyJenkins 66 4/1/2009 4/1/2009
6 additional Officers and Directors records available in full report.

Business Names
Business Name
Valeritas Inc
Valeritas Inc
Valeritas Security Corporation
VLRX

General Information
Outstanding Shares: 15,788,102 (As of 3/19/2015)
Stock Exchange: NASD
Federal Tax Id: 205321056
Fax Number: (845) 818-3588
Email Address: gen-info@Valeritas.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023